High receptor activator of Nuclear Factor Kappa Î² (RANK) expression and luminal A subtype are associated with bone metastasis in patients with breast cancer

Nyoman Gde Trizka Santhiadi; I Wayan Sudarsa; Tjokorda Gde Bagus Mahadewa

doi:10.15562/bmj.v8i3.1573

High receptor activator of Nuclear Factor Kappa Î² (RANK) expression and luminal A subtype are associated with bone metastasis in patients with breast cancer

Nyoman Gde Trizka Santhiadi ,

I Wayan Sudarsa ,

Tjokorda Gde Bagus Mahadewa ,

PDF |
DOI: https://doi.org/10.15562/bmj.v8i3.1573 |
Published: 2019-09-29

Abstract

Background

Bones are the most common distant metastasis site in breast cancer, especially in advanced stages. Bone metastasis involves continuous interaction between tumor cells, osteoblast, osteoclast, and bone matrix. There are many risk factors regarding distant metastasis sites in breast cancer patients, including breast cancer molecular subtypes and mediator known as Receptor Activator of Nuclear Factor Kappa Î² (RANK). In this study, we explore relationships between Luminal A breast cancer and RANK in association with bone metastasis site.

Method

This study is a cross-sectional analysis study conducted in Sanglah General Hospital, Bali Denpasar. Estimated sample size was measured using formula to hypothesize between two proportions, and obtained 34 patients as our minimal sample needed in this study. Data will be presented in 2x2 tables, consist of RANK Protein expression and molecular cancer subtype (Luminal A / Non-Luminal A) in row section and Metastasis (Bone Metastasis or Non-Bone Metastasis) in column section. Univariat analysis were done using comparative method between 2 categorical unrelated groups: Chi Square and Fisherâ€™s Exact Test. OR values were measured and p value <0.05 considered to be significant statistically.

Result

From these 106 patients, we used nested sampling to randomize these patients into our study sample, with total of 36 patients. The mean age of our patients is 48.64 Â± 9.86 years. Luminal A subtypes tends to metastasize into bone component compared with Non-Luminal A subtypes with p value 0.041 and OR: 3.5; with 95% CI (0.82 â€“ 14.84). Tumor with high RANK expressions tends to metastasize into bone component compared with low RANK expressions with p value 0.045 and OR 3.25; with 95% CI (0.81 â€“ 13.03)

Conclusion

There is a significant difference statistically in molecular subtype breast cancer and in RANK protein expressions between two patient groups (bone metastasis site vs other metastasis site)

References

Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J, Group EGW. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2014; 25 Suppl 3: iii124-37.
Tjindarbumi D, Mangunkusumo R. Cancer in Indonesia, present and future. Jpn J Clin Oncol. 2002;32 Suppl: S17-21.
Wahidin M, Noviani R, Hermawan S, Andriani V, Ardian A, Djarir H. Population-based cancer registration in Indonesia. Asian Pac J Cancer Prev. 2012;13:1709-10.
Jensen AO, Jacobsen JB, Norgaard M, Yong M, Fryzek JP, Sorensen HT. Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark. BMC Cancer. 2011;11:29-34.
Sterling JA, Edwards JR, Martin TJ, & Mundy GR. Advances in the biology of bone metastasis: how the skeleton affects tumor behavior. 2011; Bone;48:6-15.
Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584-93
Yoneda T, Tanaka S, Hata K. Role of RANKL/RANK in primary and secondary breast cancer. World J Orthop. 2013;4:178-85.
Ney JT, Fehm T, Juhasz-Boess I, Solomayer EF. RANK, RANKL and OPG Expression in Breast Cancer - Influence on Osseous Metastasis. Geburtshilfe Frauenheilkd. 2012;72: 385-391.
Dougall WC. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clin Cancer Res. 2012;18:326-35.
Narducci P, Bareggi R, Nicolin V. Receptor Activator for Nuclear Factor kappa B Ligand (RANKL) as an osteoimmune key regulator in bone physiology and pathology. Acta Histochem. 2011;113:73-81.
Kast K, Link T, Friedrich K, Petzold A, Niedostatek A, Schoffer O, Werner C, Klug SJ, Werner A, Gatzweiler A, Richter B, Baretton G, Wimberger P. Impact Of Breast Cancer Subtypes And Patterns Of Metastasis On Outcome. Breast Cancer Res Treat. 2015;150: 621-9.
Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28:3271-7.
Haque R, Ahmed SA, Inzhakova G, Shi J, Avila C, Polikoff J, Bernstein L, Enger SM, Press MF. Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiol Biomarkers Prev. 2012;21:1848-55.
Park HS, Ahwon L, Byung JC, Ja-Seong B, Byung JS, Sang SJ. Expression of Receptor Activator of Nuclear Kappa-B as a Poor Prognostic Marker in Breast Cancer. Journal of Surgical Oncology. 2014;110:18-22.
Gerratana L, Fanotto V, Bonotto M, Bolzonello S, Minisini AM, Fasola G, Puglisi F. Pattern of metastasis and outcome in patients with breast cancer. Clin Exp Metastasis. 2015;32:125-33.
Xiaofeng D, Ting L, Zhonghu B, Yankun Y, Xiuxia L, Jinling Z, Bozhi S. Review Article: Breast cancer instrinsic subtype classification, clinical use and future trends. Chongqing University; 2015.
Trinkaus M, Wei SO, Ethan A, Snezana P, Marion K, Hariette K, Gurmit S, Mary CG, Mark C. Examination Of The Mechanism Of Osteolysis In Patients With Metastatic Breast Cancer. Oncology Reports. 2009;21:1153-1159.
Schramek D, Sigl V, Penninger JM. RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis. Trends Endocrinol Metab. 2011;22:188-94.
Arif W. Role of Kappa-Î² Receptor Activator of Nuclear Factor, Ligand Receptor Activator of Nuclear Factor of Breast Cancer, Osteoprotegerin, and Its Ratio in Breast Primary Tumors as Metastatic Risk Factors with Bone Components of Breast Cancer Patients; 2016.